The latest Chinese CLL guidelines recommend using Bruton tyrosine kinase inhibitors (BTKi), such as ibrutinib (IB), zanubrutinib (ZB), or chemoimmunotherapy with bendamustine (BE) plus rituximab (RI) for previously untreated Chinese patients with CLL aged 65 years or older without del(17p)/TP53 mutation [7, 8]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.